Denali Therapeutics Inc.
DNLI
$19.80
$0.341.75%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/13/2026
-
TipRanks Financial Blog
5/13/2026
-
SeekingAlpha
5/12/2026
-
MarketBeat
5/12/2026
-
Tickeron - Stocks
5/11/2026
-
Simply Wall St
5/11/2026
-
MarketBeat
5/11/2026
-
TipRanks Financial Blog
5/11/2026
-
The Cerbat Gem
5/10/2026
-
TipRanks Financial Blog
5/10/2026
-
MarketBeat
5/9/2026
-
MarketBeat
5/8/2026
-
TipRanks Financial Blog
5/8/2026
-
TipRanks Financial Blog
5/8/2026
-
Zacks Investment Research
5/8/2026
-
Zacks Investment Research
5/8/2026
-
MarketBeat
5/8/2026
-
The Cerbat Gem
5/8/2026
-
MarketBeat
5/8/2026
-
MarketBeat
5/7/2026
-
Globe Newswire
5/7/2026
-
Benzinga
5/5/2026
-
Nasdaq News: Markets
5/5/2026
-
Fool.com Headlines
5/4/2026
-
Simply Wall St
5/4/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, May 7, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 866 8547
Address
161 Oyster Point Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
Country
Year Founded
Business Description
Sector
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib...
more